Almirall and Microsoft partner for dermatological drug development
Pharmaceutical Technology
FEBRUARY 1, 2024
Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology.
Almirall and Absci link for AI-driven dermatological drug development
Pharmaceutical Technology
NOVEMBER 15, 2023
Almirall has entered into a collaboration with Absci for the development and commercialisation of new treatments for dermatological ailments.
Dermatology 
130
130 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dermatology pharma Alys launches with $100m from Medicxi
pharmaphorum
FEBRUARY 12, 2024
Medicxi has combined six biotechs with dermatology medicines in development in a single drugmaker, called Alys Pharma, which starts life with $100 million in financing.
Dermatology 126
126 
Almirall announces a new research collaboration with the University of Dundee to develop an innovative and differentiated treatment approach for dermatological diseases
Pharma Mirror
APRIL 8, 2022
BARCELONA, Spain and Dundee, UK, a global biopharmaceutical company focused on skin health, today announced a research collaboration with the University of Dundee, a top-ranked university in the UK in biological sciences, to develop a novel approach against chronic and debilitating dermatology diseases where itch, or pruritus, plays a dominant role.
Dermatology 130
130 
Almirall, Microsoft team up on digital dermatology drive
pharmaphorum
FEBRUARY 1, 2024
Almirall has formed a three-year alliance with Microsoft designed to accelerate the discovery and development of personalised dermatology therapies.
Dermatology 115
115 
Journey Medical’s Emrosi Wins FDA Approval for Rosacea, Could Rival Galderma’s Oracea
XTalks
NOVEMBER 7, 2024
Maraoui said the company’s dermatology-focused sales force is “now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea.” Journey Medical plans to make Emrosi available by early 2025 through dermatology clinics and pharmacies across the US.
FDA Approval 105
105 
Interleukin inhibitors remain a strong growth driver in dermatology
Pharmaceutical Technology
JANUARY 20, 2025
If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.
Dermatology 147
147 
Fishawack Health welcomes expert-led dermatology initiative FIDE to its group
pharmaphorum
NOVEMBER 11, 2021
KNUTSFORD, United Kingdom — Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology. Kenneth B Gordon, MD, Professor and Chair of Dermatology at the Medical College of Wisconsin. November 10, 2021, UK.
Dermatology 98
98 
Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development
FDA Law Blog
NOVEMBER 10, 2024
Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.
Production 69
69 
Dermatology program brings timely and accurate diagnosis of skin conditions to underserved communities
Medical Xpress
JANUARY 24, 2023
A dermatology program first developed by the University of Missouri in 2015 can bring life-saving diagnoses of skin conditions to communities without adequate dermatologic care.
Dermatology 75
75 
Pfizer buys immuno-inflammatory firm Arena Pharmaceuticals for $6.7b
Outsourcing Pharma
DECEMBER 13, 2021
The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.
Cardiology 145
145 
4th Dermatology Drug Development Summit Europe
pharmaphorum
MAY 9, 2023
4th Dermatology Drug Development Summit Europe Mike.Hammerton Tue, 05/09/2023 - 20:11 Bookmark this
Dermatology 52
52 
Champion Innovation at the 7th Dermatology Drug Development Summit
pharmaphorum
OCTOBER 9, 2023
Champion Innovation at the 7th Dermatology Drug Development Summit Mike.Hammerton Mon, 09/10/2023 - 14:39 Bookmark this
Dermatology 52
52 
Dermatology drug developer taps into Veeva engagement tool
Outsourcing Pharma
MAY 23, 2022
With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.
Dermatology 52
52 
8th Dermatology Drug Development Summit
pharmaphorum
OCTOBER 2, 2024
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
Dermatology 52
52 
Sun Pharma to buy Concert Pharmaceuticals for $576m
Pharmaceutical Technology
JANUARY 19, 2023
Concert’s patent portfolio includes oral Janus kinases JAK1/2 inhibitor, deuruxolitinib, to treat Alopecia Areata, an autoimmune dermatological disease. The company also noted that the deal will strengthen its global dermatology franchise with the addition of a late-stage product in an area with significant unmet need.
Dermatology 147
147 
Standardized Rater Training to Meet the Demands of Dermatology Growth and Complexities
WCG Clinical
OCTOBER 9, 2023
The dermatology market is embarking on tremendous growth and sponsors need to be ready. Over the last 12 months, dermatology-focused studies have increased by roughly 20%, with top focus areas including psoriasis, atopic dermatitis, and alopecia. This rapid growth brings new challenges. Efficiency and speed are critical.
Dermatology 59
59 
Smartphone-based skin cancer diagnostic certified for use in UK
pharmaphorum
APRIL 29, 2022
An artificial intelligence-powered digital tool for diagnosing skin cancers developed by Skin Analytics has been cleared in the UK as a Class IIA medical device, setting up broader use of the technology in patient assessments.
Dermatology 145
145 
DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit
BioTech 365
DECEMBER 3, 2020
DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit LA JOLLA, Calif.–(BUSINESS –(BUSINESS WIRE)–DermTech, Inc.
Dermatology 40
40 
KFA-115 by Novartis for Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
US companies drive 2023 drug launches positioned for blockbuster success by 2028
Pharmaceutical Technology
MAY 30, 2023
which is the licensee of lebrikizumab, recently reported favourable outcomes for lebrikizumab through a novel secondary analysis of the Phase III clinical development programme. Despite this, only one oncological therapy, namely epcoritamab developed by Genmab AS, secures a place among the top five drug launches of 2023.
Drugs 264
264 
Optimizing Endpoint Assessments for Dermatology Studies
WCG Clinical
SEPTEMBER 20, 2023
Welcome to the recorded session of ‘Optimizing Endpoint Assessments for Dermatology Studies.’ In this insightful webinar, we take a deep dive into dermatology trials and discuss how standardizing rater qualification and training can solve common challenges and protect the quality and integrity of endpoint data.
Dermatology 40
40 
US FDA accepts Arcutis’ NDA for seborrheic dermatitis therapy
Pharmaceutical Technology
APRIL 19, 2023
The drug is taken once a day and is currently being developed for the treatment of inflammatory dermatoses, mainly in hair-bearing body areas such as the face, the trunk and the scalp. The regulator has set 16 December 2023 as a prescription drug user fee act (PDUFA) target action date for the decision on the application.
Dermatology 130
130 
Animated and Live Action Content Delivers Precise Training for Dermatology Studies
WCG Clinical
MARCH 30, 2023
WCG’s InvestigatorSpace® offers customizable training solutions to bring accurate and detailed training to life while reducing the time spent on developing assets by an average of 60%. WCG collaborated with study teams and clinical experts to develop the training modules.
Dermatology 52
52 
Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology
BioTech 365
MAY 20, 2021
Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology PBI-100 is a topical treatment being developed for people living with mild to moderate … Continue reading →
Dermatology 40
40 
Incannex engages QPS for CannQuit and ReneCann
Pharmaceutical Technology
APRIL 17, 2023
The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. The company will help in managing the clinical trials of the products once the regulators provide approvals for the proposed research and development programmes.
Dermatology 130
130 
Sanofi snaps up acne vaccine developer Origimm Bio
pharmaphorum
DECEMBER 1, 2021
The post Sanofi snaps up acne vaccine developer Origimm Bio appeared first on. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia. Photo by Scott Webb on Unsplash.
Vaccine 105
105 
Incyte signs partnership agreement with CMS for ruxolitinib cream
Pharmaceutical Technology
DECEMBER 5, 2022
Incyte has signed a partnership and licence agreement with CMS subsidiary CMS Aesthetics to develop and market ruxolitinib cream to treat autoimmune and inflammatory dermatologic ailments in Greater China and some Southeast Asian countries. Incyte will also receive royalty payments on the net product sales in the territory of CMS.
Dermatology 130
130 
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
BioTech 365
SEPTEMBER 23, 2020
23, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that positive results from the two pivotal Phase III CAMP (Cantharidin … Continue reading →
Dermatology 40
40 
Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
pharmaphorum
SEPTEMBER 16, 2022
Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. Findings presented at EADVC 2022.
Dermatology 100
100 
MIT Researchers Develop World’s First Digital Fabric That Can Measure and Store Health Data
XTalks
JUNE 10, 2021
Related: Google Launches AI-Based Dermatology Assist Tool. As such, they say digital devices integrated into fibers could lead to fabrics with digital system capabilities for applications in physiological monitoring, human-computer interfaces and on-body machine-learning.
Research 111
111 
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
The Pharma Data
OCTOBER 29, 2020
30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. vice president of immunology development at Lilly.
Dermatology 52
52 
Lebrikizumab Could Soon Be a New Treatment for Atopic Dermatitis
XTalks
APRIL 17, 2023
These results are very promising for patients with atopic dermatitis,” said Jonathan Silverberg, MD, professor of dermatology at George Washington University School of Medicine & Health Sciences and co-investigator of the studies, in the company’s press release.
Dermatology 97
97 
LEO Pharma and ICON plc collaborate to improve outcomes for dermatology patients
Outsourcing Pharma
MARCH 14, 2023
A strategic partnership between LEO Pharma and ICON plc, a clinical development company, was announced on March 10.
Dermatology 52
52 
Leading innovators in anti-influenza antibody compositions for the pharmaceutical industry
Pharmaceutical Technology
MAY 8, 2023
This protein also serves as a target for neutralizing antibodies, which can be used to develop for therapeutic as well as diagnostic applications. Hemagglutinin (HA), an envelope glycoprotein on the influenza virion enables the virus to enter and spread between cells.
Antibody 246
246 
KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Verrica’s Dr. Lawrence Eichenfield Speaks About FDA Approval of New Drug for Common Skin Infection – Xtalks Life Science Podcast Ep. 121
XTalks
AUGUST 2, 2023
Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases that require medical interventions. Tune into this episode to learn more about YCANTH and its approval, as well as the changing landscape of dermatology, from Dr. Eichenfield.
Life Science 52
52 
Mount Sinai researchers identify mechanisms that are essential for proper skin development
Scienmag
FEBRUARY 18, 2021
Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development on February 18.
Ensuring successful digital outreach and retention in atopic dermatitis trials
pharmaphorum
JULY 5, 2022
With more than 500 dermatology clinical trials currently underway, it is often heard that there is a ‘’competition for participants’’. To help companies develop a nuanced understanding of how to optimise digital recruitment efforts to connect with a more diverse community of patients, Clariness’ whitepaper outlines.
Trials 118
118 
Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
LEO Pharma’s new R&D lead on driving agility in drug development
pharmaphorum
MARCH 24, 2021
After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. The post LEO Pharma’s new R&D lead on driving agility in drug development appeared first on. Is it a disease that has a high symptomatic disease burden, but is otherwise more of a nuisance?”
Development 52
52 
Let's personalize your content